title: Association between insulin-like growth factor-2 expression and prognosis after transcatheter arterial chemoembolization and octreotide in patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  To investigate the association between the change of IGF-2 level in serum after transcatheter arterial chemoembolization (TACE) and hepatocellular carcinoma (HCC) progression, especially in relation to metastasis.
  
  
  METHODS
  IGF-2 in serum was measured by quantitative sandwich enzyme-linked immunosorbent assay before, 3 days and 4 weeks after TACE in 60 patients with HCC. The occurrence of HCC metastasis was also evaluated, 3 months after TACE.
  
  
  RESULTS
  (1) The average serum level of IGF-2 in the 60 patients with HCC was 136.5 ± 87.3 pg/ml; (2) A tendency for increase was observed with heterogenous uptake of octreotide and portal vein thrombosis. Metastatic foci were found in 37/38 patients in the group with IGF-2 increasing (97.0%), in contrast to 3/22 (13.6%) patients with IGF-2 decrease.
  
  
  CONCLUSIONS
  The increase of IGF-2 level in serum appears to be associated with the occurrence of metastatic HCC after TACE and chemotherapy.
authors.affiliation: Department of Interventional Radiology, Hunan Provincial Tumor Hospital, Changsha, China.
authors.forename: Zheng-Ping
authors.initials: ZP
authors.lastname: Xiong
authors.forename: Fang
authors.initials: F
authors.lastname: Huang
authors.forename: Meng-Hou
authors.initials: MH
authors.lastname: Lu
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D005260:Female; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis*; D008113:Liver Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000008:administration & dosage*; D011379:Prognosis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007335:Insulin-Like Growth Factor II; D015282:Octreotide